Related Experiment Video
Updated: Jan 25, 2026
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
ARNi: A Novel Approach to Counteract Cardiovascular Diseases
Massimo Volpe1,2, Speranza Rubattu3,4, Allegra Battistoni5
1Department of Clinical and Molecular Medicine; School of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy. massimo.volpe@uniroma1.it.
Insights
New drugs called angiotensin receptor-neprilysin inhibitors (ARNIs) show promise for treating cardiovascular diseases (CVDs). These ARNIs target multiple pathways, offering new hope for managing conditions like heart failure and hypertension.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Cardiovascular diseases (CVDs) remain a leading global health burden, with risk factors inadequately controlled.
- Existing treatments targeting the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system are effective but insufficient.
- Dysregulation of the natriuretic peptide (NP) system is implicated in CVD development, necessitating novel therapeutic strategies.
Purpose of the Study:
- To introduce angiotensin receptor-neprilysin inhibitors (ARNIs) as a novel therapeutic class for cardiovascular diseases.
- To highlight the dual mechanism of ARNIs in counteracting angiotensin II effects and enhancing NP activity.
- To explore the expanding therapeutic potential of ARNIs beyond heart failure with reduced ejection fraction.
Main Methods:
- Review of existing literature on neurohormonal systems in cardiovascular pathophysiology.
- Analysis of the mechanism of action of angiotensin receptor-neprilysin inhibitors (ARNIs).
- Evaluation of clinical evidence supporting ARNi efficacy in heart failure with reduced ejection fraction.
Main Results:
- ARNIs effectively inhibit the renin-angiotensin-aldosterone system (RAAS) and potentiate the natriuretic peptide (NP) system.
- ARNIs have demonstrated significant benefits in patients with heart failure with reduced ejection fraction.
- Emerging data suggest potential applications for ARNIs in other cardiovascular conditions.
Conclusions:
- Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a promising advancement in cardiovascular therapeutics.
- The dual-acting mechanism of ARNIs offers a novel approach to managing complex cardiovascular diseases.
- Future research is warranted to establish the role of ARNIs in heart failure with preserved ejection fraction and hypertension.
Abstract:
Cardiovascular diseases (CVDs) still represent the greatest burden on healthcare systems worldwide. Despite the enormous efforts over the last twenty years to limit the spread of cardiovascular risk factors, their prevalence is growing and control is still suboptimal. Therefore, the availability of new therapeutic tools that may interfere with different pathophysiological pathways to slow the establishment of clinical CVDs is important. Previously, the inhibition of neurohormonal systems, namely the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system, has proven to be useful in the treatment of many CVDs. Attempts have recently been made to target an additional hormonal system, that of the natriuretic peptides (NPs), which, when dysregulated, can also play a role in the development CVDs. Indeed, a new class of drug, the angiotensin receptor-neprilysin inhibitors (ARNi), has the ability to counteract the effects of angiotensin II as well as to increase the activity of NPs. ARNi have already been proven to be effective in the treatment of heart failure with reduced ejection fraction. New evidence has suggested that, in the next years, the field of ARNi application will widen to include other CVDs, such as heart failure, with preserved ejection fraction and hypertension.
Related Concept Videos
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
01:14Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:29Assessment of the Cardiovascular System II: Inspection
Head and Neck
01:25Assessment of the Cardiovascular System IV: Auscultation
Normal Heart Sounds
S1 (First Heart Sound)-
S1 is made by the closure of the mitral and tricuspid valves (atrioventricular valves), marking the beginning of systole.
S2 (Second Heart Sound)-
S2 is made by the closure of the aortic and pulmonic valves (semilunar valves), marking the end of the systole.